Is Male Infertility an Early Warning of More Serious Diseases?

Review argues 1–6% of infertile men have undetected life-threatening pathology, yet workup stops at semen analysis

Journal: Endocrinology | Published: 2026-03-06 | Type: Review | PMID: 41486877 Authors: Dolores J. Lamb (Children's Mercy Hospital, Division of Pediatric Urology — a senior figure in male infertility genetics) Funding/COI: National Cancer Institute, NIH HHS. COI not disclosed.

Summary

Male infertility affects roughly half of all infertile couples, yet the clinical workup for the male partner routinely ends at a semen analysis while the female undergoes exhaustive evaluation. This review synthesizes three decades of evidence showing that infertile men carry elevated rates of endocrine disorders, malignancies, genetic diseases, and developmental anomalies — and that as semen quality worsens, systemic disease risk increases. The central argument: poor semen parameters are a sentinel marker, not just a fertility problem.

Claims

• Approximately 12% of couples worldwide are infertile; male factor contributes to roughly 50% of cases
• In studies from the early 1990s through the present, 1–6% of unselected infertile men presenting for clinical evaluation had significant or life-threatening pathology (endocrine abnormalities, malignancies, developmental anomalies, genetic diseases)
• Infertile men show increased overall morbidity and mortality compared to fertile men, though mechanisms are poorly understood
• As semen parameters decline, risk of multiple systemic health conditions rises — reviewed as a gradient relationship
• Despite these findings, the male partner in an infertile couple typically receives only a routine semen analysis

Study Quality

This is a narrative review by a single author, not a systematic review or meta-analysis. No PRISMA protocol, no pre-registration, no explicit inclusion/exclusion criteria for cited studies. The 1–6% pathology figure is drawn from a range of studies spanning 30+ years with varying populations, definitions of "significant pathology," and referral biases — the spread itself signals how heterogeneous that evidence base is. The morbidity and mortality claims are real findings from the literature but the review doesn't quantify them with pooled effect sizes; it reports them qualitatively.

The author is a recognized researcher in male reproductive genetics, which lends credibility but also means the review reflects one expert's synthesis rather than a systematic one. NIH Cancer Institute funding is appropriate given the malignancy angle, but the exact scope of funding in relation to this review isn't detailed.

Red Flags

• Narrative review with no stated methodology — cherry-picking risk is inherent
• COI not disclosed for a high-profile author with likely industry relationships; the absence of a declaration is itself a flag
• The 1–6% pathology range is wide enough to be almost uninformative without understanding the populations behind each endpoint
• Mortality/morbidity claims are asserted without presenting pooled effect sizes or specific hazard ratios
• Single-author reviews in high-stakes clinical areas tend to reflect the author's research program more than the full evidence base

Strengths

• Draws attention to a genuine and well-documented clinical gap: the asymmetric rigor applied to male vs. female infertility workup
• Spans three decades of evidence, providing historical context for an underappreciated problem
• Framing male infertility as a systemic health marker rather than an isolated reproductive issue is clinically meaningful and increasingly supported by prospective cohort data
• NIH-funded work with an author who has long-standing expertise in the genetics of male infertility

Verdict

The core claim — that infertile men are systematically under-evaluated and that poor semen quality flags broader systemic disease — is real and worth attention. The evidence supporting it exists. But this review doesn't do that evidence the justice of a systematic treatment: no pooled statistics, no defined search strategy, no COI statement. It reads as an expert advocacy piece pushing a legitimate clinical message, not a rigorous synthesis. Worth reading for the argument and as an entry point to the primary literature it cites; not citable as quantitative evidence on its own.